Figure 3
From: Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
Synergy of direct-acting HCV antivirals velpatasvir (a)-(d) and elbasvir (e)-(h) with remdesivir in Calu-3 cells infected with SARS-CoV-2. (a) Three-dimensional plot showing synergy of combinations of velpatasvir (x-axis, up to 40 μM) and remdesivir (y-axis, up to 0.6 μM). Z-axis indicates CPE Inhibition (%). Marker colored using a gradient from blue (0% CPE inhibition) to red (100% CPE inhibition). Green—highest concentration of velpatasvir and remdesivir alone, reaching only ~ 20% Inhibition of CPE. Dashed line indicates dose response results of remdesivir and velpatasvir alone. (b) Two-dimensional representation of dose response interaction matrix. X-axis—Remdesivir (up to 10 μM), y-axis: Velpatasvir (up to 40 μM). Color gradient indicates Inhibition of CPE (%); white—0%, red—100%. (c) Topographic two-dimensional map of synergy scores determined in synergyfinder 34 from the data in (a) and (b), axes as in (b), color gradient indicates synergy score (red—highest score). (d) Three-dimensional surface plot representing synergy score (z-axis) for each compound combination. X-axis: remdesivir up to 10 μM, y-axis: velpatasvir up to 40 μM. (e), (f), (g), (h) as in (a), (b), (c), (d) but with elbasvir instead of velpatasvir. (i) Dose response of remdesivir alone (black) and in combination with 10 μM velpatasvir (red). (j) Dose response of remdesivir alone (black) and in combination with 10 μM elbasvir (red).
